Re: Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: Systematic Review and Meta-analysis of Randomized trials

被引：1
作者：
Landgren, Ola [1 ]
Dunleavy, Kieron [2 ]
Wilson, Wyndham H. [2 ]
机构：
[1] NCI, Med Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[2] NCI, Metab Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
来源：
JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2009年 / 101卷 / 18期
关键词：
RESPONSE DURATION; FREE SURVIVAL; CYCLOPHOSPHAMIDE; PROGRESSION; THERAPY;
D O I：
10.1093/jnci/djp255
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1287 / 1288
页数：3
相关论文
共 7 条
  • [1] Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas:: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)
    Forstpointner, Roswitha
    Unterhalt, Michael
    Dreyling, Martin
    Boeck, Hans-Peter
    Repp, Roland
    Wandt, Hannes
    Pott, Christiane
    Seymour, John F.
    Metzner, Bernd
    Haenel, Annette
    Lehmann, Tanja
    Hartmann, Frank
    Einsele, Hermann
    Hiddemann, Wolfgang
    [J]. BLOOD, 2006, 108 (13) : 4003 - 4008
  • [2] Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly X 4 schedule
    Ghielmini, M
    Schmitz, SFH
    Cogliatti, SB
    Pichert, G
    Hummerjohann, J
    Waltzer, U
    Fey, MF
    Betticher, DC
    Martinelli, G
    Peccatori, F
    Hess, U
    Zucca, E
    Stupp, R
    Kovacsovics, T
    Helg, C
    Lohri, A
    Bargetzi, M
    Vorobiof, D
    Cerny, T
    [J]. BLOOD, 2004, 103 (12) : 4416 - 4423
  • [3] Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma - A randomized phase II trial of the minnie pearl cancer research network
    Hainsworth, JD
    Litchy, S
    Shaffer, DW
    Lackey, VL
    Grimaldi, M
    Greco, EA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (06) : 1088 - 1095
  • [4] Hochster HS, 2007, J CLIN ONCOL, V25
  • [5] Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study
    Hochster, Howard
    Weller, Edie
    Gascoyne, Randy D.
    Habermann, Thomas M.
    Gordon, Leo I.
    Ryan, Theresa
    Zhang, Lijun
    Colocci, Natalia
    Frankel, Stanley
    Horning, Sandra J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (10) : 1607 - 1614
  • [6] Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial
    van Oers, Marinus H. J.
    Klasa, Richard
    Marcus, Robert E.
    Wolf, Max
    Kimby, Eva
    Gascoyne, Randy D.
    Jack, Andrew
    van't Veer, Mars
    Vranovsky, Andrei
    Holte, Harald
    van Glabbeke, Martine
    Teodorovic, Ivana
    Rozewicz, Cynthia
    Hagenbeek, Anton
    [J]. BLOOD, 2006, 108 (10) : 3295 - 3301
  • [7] Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: Systematic Review and Meta-analysis of Randomized Trials
    Vidal, Liat
    Gafter-Gvili, Anat
    Leibovici, Leonard
    Dreyling, Martin
    Ghielmini, Michele
    Schmitz, Shu-Fang Hsu
    Cohen, Amos
    Shpilberg, Ofer
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (04): : 248 - 255
1